itional risk factors, antiplatelet regimen, invasive or conservative management, and established prognostic markers. 3 The results are biologically plausible and consistent with long-standing previous research. Fibrin clots were reported to obstruct epicardial arteries in patients dying of heart attacks in 1969, although 50 years ago the observation was considered a post-mortem artefact. 4 In 1980, a follow-up of 1510 middle-aged men identified plasma fibrinogen and coagulation factor VII as independent predictors of fatal and non-fatal coronary events, with a stronger relationship than for cholesterol, blood pressure, or smoking. 5 The relevance of this association was probably under-rated at that time. In parallel, a placebo-controlled trial of 878 patients reported a dramatic effect of warfarin in reducing deaths and recurrent infarctions over a 2-year follow-up. 6 In 1985, impaired vascular release of tissue-type plasminogen activator (t-PA) and elevated circulating plasminogen activator inhibitor-1 (PAI-1) were found to characterize young survivors of heart attacks, particularly if hypertriglyceridaemic. 7 In 1986, fibrinolytic therapy vs. placebo in acute heart attack patients significantly improved survival. 8 In the long term, anticoagulation, alone or with aspirin, reduced ischaemic outcomes vs. aspirin alone up to 4 years after a first heart attack. 9 In primary prevention, in a high-risk population, low-intensity warfarin, aspirin, or their combination reduced adverse cardiac outcomes vs. placebo, with warfarin acting chiefly on fatal events. 10 More recently, low-dose rivaroxaban vs. placebo, on top of dual antiplatelet therapy, was found to prevent fatal outcomes during the first year after an acute coronary syndrome, albeit at an increased risk of major bleeding.
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The same low-dose rivaroxaban on top of aspirin prevented fatal and non-fatal events in stable cardiovascular disease patients compared with aspirin alone. 1 Thus, excessive fibrin formation and delayed fibrin dissolution have repeatedly emerged as affecting cardiovascular events, particularly fatal ones. And treatments altering these biochemical processes have consistently reduced the occurrence of adverse events ( Figure 1 ). When fibrinopeptides A and B at the tips of soluble fibrinogen are clipped off by thrombin to form fibrin, extremely adhesive sites are exposed that stick to each other in an overlapping and criss-cross pattern 11 ( Figure 1 ). Insoluble fibrils polymerize into a soft tridimensional net that traps red and white cells, platelets, and other particles into a gelatinous mass. In a healthy vascular environment, fibrin is tightly regulated in space and time. Normal fibrin is rich in lysine residues that attract the kringle domains of circulating plasminogen and plasminogen activators, with conversion of plasminogen to plasmin. The latter degrades fibrin into D-dimers and other soluble fragments ( Figure 1) . Ageing, hypertension, high body mass, hyperglycaemia, insulin resistance, hypertriglyceridaemia, increased levels of lipoprotein(a) [Lp(a)], and oxidative stress are known to be associated with reduced endothelial release of t-PA, enhanced endothelial and platelet release of PAI-1, and enhanced generation of complement C3 and of the thrombin-activatable fibrinolysis inhibitor (TAFI). [12] [13] [14] [15] [16] TAFI delays fibrinolysis by removing lysine residues from partially degraded fibrin. 14 C3 also contributes to impaired fibrinolysis. 15 Lp(a) contains kringles that compete with the fibrin binding of t-PA and plasminogen. 16 In addition, coagulation factor XIII, activated by thrombin, consolidates fibrin through cross-links that further impair fibrinolysis. 17 Thus, hypofibrinolysis underlies virtually all the major cardiovascular risk conditions. The PLATO biomarker substudy reported by Sumaya and colleagues is particularly relevant, being prospective and among the largest of its kind. 3 Criteria for entering into the substudy are not specified, apart from survival to discharge; the patients' characteristics, however, appear comparable with those of the overall PLATO trial. 3, 18 The 1-year rate of death, myocardial infarction, and stroke was 8.4%, comprising 145 deaths, of which 125 were cardiovascular. Despite some caveats, such as exclusion of patients with a high bleeding tendency, lower statin use among patients in the top quartile of clot lysis time, and lack of correction for time of day and for multiple comparisons, the investigators' methodology should be commended. Samples were collected after a median of 6 days from admission to avoid the effects of early heparin administration. Fibrin clot lysis time was measured in duplicate, blinded to clinical data, in a central laboratory, using a commercially available spectrophotometer and a validated, controlled assay. The effects of plasma fibrinogen were explored in a subgroup. Statistical analyses were centralized, independent, non-parametric, adjusted for 15 clinical characteristics (model 1) and for 6 additional biomarkers (model 2); the latter accounted for variations in infarct size, heart failure prevalence and severity, inflammatory state, and renal impairment. Clot lysis time was measured in a 25 ml plasma sample as the time taken for maximum turbidity to fall by 50%, after addition of thrombin and t-PA. Patients belonging to the top quartile showed a >5 min longer lysis time compared with patients in the lowest quartile (>14.8 min vs. <9.4 min). A 5 min delay relative to a 25 ml sample might translate into a considerably greater delay when applied to a several cubic millimetre occlusive thrombus in vivo. Can these results be generalized? The answer is: not to those excluded from the overall PLATO trial or from the biomarker substudy, but otherwise probably yes. What are the potential determinants of clot lysis time as assessed in vitro? Possibilities, among many, include plasminogen, plasminogen activators and their inhibitors, TAFI, C3, factor XIII, antiplasmin, Lp(a), fibrin structure, 11 and protein glycation/oxidation ( Figure 1) . The findings of the study by Sumaya et al. expand our understanding of the potential mechanisms contributing to the variability in presentations, clinical outcomes, and recurrences of patients with acute coronary syndromes. After plaque rupture or fissuration, which is considered the prevalent event leading to coronary thrombosis, the process of thrombus formation relies on the interplay between generation and dissolution of the fibrin network, which constitutes the architecture for thrombus development. Within this framework, swift endogenous fibrinolysis is expected to exert a protective action, limiting the propagation of formed thrombi and preventing total coronary occlusion. In contrast, prolonged endogenous fibrinolysis might reflect resistance of thrombi to lysis and be associated with worse outcomes, as observed in the present study. Thus, the addition to prognostic models of this new marker of risk might contribute to a better stratification and treatment of acute coronary syndrome patients.
The prediction of reduced survival by prolonged endogenous fibrinolysis in patients with a recent acute coronary syndrome is indeed compelling as it appears to reflect, in a subacute setting, the improved survival by pharmacological thrombolysis in patients with acute myocardial infarction. The major potential implications are at
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